<DOC>
	<DOCNO>NCT03080987</DOCNO>
	<brief_summary>The primary purpose study assess safety tolerability JNJ-64179375 Part 1 2 .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics , Immunogenicity , Pharmacodynamics JNJ-64179375 Healthy Male Japanese Participants</brief_title>
	<detailed_description />
	<criteria>Must born Japan Japanese parent maternal paternal Japanese grandparent Body mass index ( weight kg/m^2 ) 18 27 kilogram per square meter ( kg/m^2 ) ( inclusive ) , body weight great 50 kg less 100 kg Generally good health basis physical examination , medical history , vital sign , laboratory test , electrocardiogram ( ECGs ) cardiac telemetry perform Screening and/or prior administration initial dose study drug Must sign inform consent form ( ICF ) indicate understands purpose , procedure require , study willing participate study History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , bleed thrombotic disorder ( include personal family history abnormal bleeding assess detailed bleed history blood dyscrasia ) , underlie coagulopathy may lead clinically relevant bleeding risk , autoimmune disease , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude subject could interfere interpretation study result Acute illness , include upper respiratory infection ( without fever ) , within 7 day prior study drug administration major illness hospitalization within 1 month prior study drug administration Clinically significant abnormal physical exam Screening Day 1 Clinically significant abnormal vital sign Screening , Day 1 , Day 1 ( predose ) determine investigator appropriate designee Clinically significant abnormal 24hour Holter electrocardiogram ( ECG ) , cardiac telemetry , ECG Screening , Day 1 , Day 1 ( predose ) determine investigator appropriate designee</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>